金融监管总局答每经问：寿险公司去年以来压降成本3500亿元

Core Viewpoint - The news highlights the achievements and ongoing reforms in China's financial industry during the "14th Five-Year Plan" period, emphasizing the enhancement of regulatory frameworks and the promotion of financial stability. Group 1: Financial Regulatory Enhancements - The Financial Regulatory Administration has made significant progress in improving the modern financial enterprise system during the "14th Five-Year Plan" period, including the implementation of a mechanism linking preset interest rates to market rates and dynamic adjustments [3] - The revision of important financial laws, such as the Banking Supervision Law and the Insurance Law, is accelerating, with 171 regulatory documents issued over the past five years to enhance the regulatory framework [4] - Regulatory effectiveness has been significantly improved through a focus on substantial risks and practical issues, with a tiered regulatory approach applied to 41 key institutions while delegating regulatory authority to 112 small and medium-sized insurance institutions [4] Group 2: Financial Stability and Risk Management - The China Securities Regulatory Commission (CSRC) emphasizes maintaining market stability by implementing early warning systems and enhancing cross-market risk prevention mechanisms [6] - The bond default rate in the exchange market remains low at around 1%, with significant progress in the rectification of private equity funds, resulting in the clearance of approximately 7,000 zombie institutions [7] - A comprehensive deterrent system has been established to combat financial fraud, with over 700 cases and leads transferred to law enforcement agencies in the past five years [7] Group 3: Investor Protection Initiatives - The introduction of new regulations has improved investor protection, including measures for compensation in cases of fraud and the establishment of a structured investor protection system [7][8] - Landmark cases, such as the compensation of approximately 2.46 billion yuan for investors in the Kangmei Pharmaceutical case, demonstrate the effectiveness of investor rights protection efforts [8]